Related Experiment Video
Updated: Apr 16, 2026
09:15
Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens
Published on: May 23, 2014
23.8K
Endometrial stromal sarcoma: a rare entity.
Salma Jabeen1, Shahnaz Anwar1, Naheed Fatima1
1Obstetrics and Gynaecology, Quaid-e-Azam Medical College, Bahawalpur.
Summary
Low Grade Endometrial Stromal Sarcoma (LGESS) is a rare, hormone-sensitive gynecological tumor. Early diagnosis is challenging, often confirmed post-hysterectomy, but treatment options exist for recurrence.
Area of Science:
- Gynecologic Oncology
- Reproductive Endocrinology
Background:
- Endometrial Stromal Sarcoma (ESS) is a rare, hormone-sensitive gynecological malignancy.
- It predominantly affects pre-menopausal women, posing diagnostic challenges.
- Pre-operative diagnosis is often difficult, with confirmation frequently occurring after hysterectomy for presumed benign conditions.
Observation:
- A case of Low Grade Endometrial Stromal Sarcoma (LGESS) presented in a 21-year-old woman with irregular vaginal bleeding.
- Initial clinical diagnosis suggested a uterine fibroid due to rapid enlargement.
- Endometrial sampling revealed ESS, later confirmed by hysterectomy specimen analysis.
Findings:
- Diagnostic clues for ESS can be obtained through endometrial sampling, ultrasound, and MRI.
- Complete surgical resection offers a cure for early-stage disease.
- Adjuvant therapies are available for managing recurrent endometrial stromal sarcoma.
Implications:
- Clinicians should consider LGESS in young women presenting with irregular bleeding and rapidly enlarging fibroids.
- Improved pre-operative diagnostic strategies are crucial for timely ESS management.
- Understanding the hormone sensitivity of ESS informs treatment and recurrence management strategies.
